Pharvaris (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan Sells 29,070 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 29,070 shares of the company’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $30.32, for a total transaction of $881,402.40. Following the completion of the sale, the director owned 355,167 shares in the company, valued at approximately $10,768,663.44. This trade represents a 7.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Wednesday, April 29th, Johannes Gerardus Chri Schikan sold 3,830 shares of Pharvaris stock. The stock was sold at an average price of $30.07, for a total transaction of $115,168.10.
• On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total transaction of $3,003.00.
• On Wednesday, April 22nd, Johannes Gerardus Chri Schikan sold 7,000 shares of Pharvaris stock. The stock was sold at an average price of $30.05, for a total transaction of $210,350.00.

Pharvaris Stock Performance

Shares of PHVS opened at $29.44 on Friday. The stock has a market cap of $1.93 billion, a PE ratio of -8.74 and a beta of -2.34. Pharvaris N.V. has a fifty-two week low of $14.59 and a fifty-two week high of $31.14. The firm’s 50-day simple moving average is $27.62 and its two-hundred day simple moving average is $26.03.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.15). Equities research analysts predict that Pharvaris N.V. will post -3.19 EPS for the current year.

Key Headlines Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Insiders still retain large, meaningful stakes after the sales, which can indicate alignment with shareholders and limit the likelihood of continued big disposals. Examples: director Johannes Schikan remains a large shareholder (~355k shares after sales) and others still hold six?figure stakes. SEC Filing
• Neutral Sentiment: Commentary noting that director sales may matter less than upcoming company catalysts — suggests investors should watch near?term clinical/regulatory milestones rather than focus only on the trades. For Pharvaris Investors, the Director’s Sale Matters Less Than What’s Coming Next
• Negative Sentiment: Anne Lesage sold multiple blocks (3,700; 19,200; 21,700 shares) across April 29–30 at ?$30.08–$30.26, reducing her position by as much as ~27.8% in filings and generating >$1.34M in proceeds — a signal that prompted selling pressure. SEC Filing
• Negative Sentiment: Peng Lu executed two sales (3,733 and 15,000 shares) on April 29–30 at ?$30.06–$30.24, cutting ownership by up to ~18.5% and raising roughly $565.8k — another substantial insider liquidity event. SEC Filing
• Negative Sentiment: Director Johannes Gerardus Chri Schikan sold two blocks (3,830 and 29,070 shares) on April 29–30 at ?$30.07–$30.32, a ~7.6% cut in his holdings and ~ $996.6k in disclosed proceeds — adding to the overall sell pressure. SEC Filing

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PHVS. Geode Capital Management LLC lifted its position in Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after purchasing an additional 15,769 shares during the period. JPMorgan Chase & Co. lifted its position in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the period. Legal & General Group Plc lifted its position in Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares during the period. Amundi lifted its position in Pharvaris by 2,741,600.0% during the second quarter. Amundi now owns 27,417 shares of the company’s stock valued at $489,000 after purchasing an additional 27,416 shares during the period. Finally, The Manufacturers Life Insurance Company raised its position in Pharvaris by 19.2% in the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock worth $860,000 after acquiring an additional 7,879 shares during the period.

Analysts Set New Price Targets

Several research analysts have recently issued reports on PHVS shares. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a research note on Tuesday, March 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Royal Bank Of Canada dropped their target price on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research note on Monday, April 6th. Wedbush upped their target price on shares of Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 7th. Finally, Wolfe Research started coverage on shares of Pharvaris in a research note on Thursday, April 9th. They issued an “outperform” rating and a $42.00 target price on the stock. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $42.73.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.